Celadon Pharmaceuticals Plc (CEL.L)

101.49 -0.01 (-0.01%) As of 09:47AM BST. Market open.

Celadon Pharmaceuticals Plc

32-33 Cowcross Street
London EC1M 6DF
United Kingdom
44 20 3150 0252
https://celadonpharma.com/

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 24

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James Gareth Short	Co-Founder, CEO & Executive Director	246.15k	N/A	1968
Mr. Paul Allen	Co-Founder	N/A	N/A	N/A
Mr. Jonathan Paul Turner	CFO & Director	N/A	N/A	1978
Iqbal Gill	Chief Scientific Officer	N/A	N/A	N/A
Ms. Kerin Williams	Company Secretary	N/A	N/A	1970

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

Corporate governance

Celadon Pharmaceuticals Plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.